SequelSEC

Evommune, Inc. EVMN

Pharmaceutical Preparations · CIK 0002044725 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-06-30
Operating income
-$34.90M
Fiscal year ended 2026-06-30
Free cash flow
-$20.50M
Fiscal year ended 2026-06-30

Evommune, Inc. (EVMN) reported revenue of $0 and net income of -$32.25M for the fiscal year ended 2026-06-30. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from Evommune, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Evommune, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Revenue$0$0$0$10.00M$0$3.00M$0Unavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$34.90M-$23.95M-$29.72M-$13.33M-$22.99M-$15.03M-$21.45M-$16.52M
Net income-$32.25M-$21.67M-$28.27M-$12.48M-$13.56M-$14.56M-$20.73M-$15.92M
Research & development$26.41M$17.32M$20.40M$19.64M$19.64M$14.36M$17.83M$13.29M
Weighted-average diluted sharesshares 36.14Mshares 33.67MUnavailableshares 1.55Mshares 1.54Mshares 1.53MUnavailableshares 1.52M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0$0$0
Diluted EPS$-0.89$-0.64Unavailable$-8.07$-8.80$-9.48Unavailable$-10.47
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$8.48M$6.64M$9.31M$3.69M$3.36M$3.67M$3.62M$3.23M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Evommune, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash & equivalents$60.03M$48.32M$44.06M$26.82M$61.84M$5.70M$16.26M$18.15M
Total assets$301.95M$322.46M$224.95M$84.54MUnavailableUnavailable$76.06MUnavailable
Current assets$204.25M$215.86M$153.48M$81.94MUnavailableUnavailable$73.99MUnavailable
Total liabilities$24.36M$17.90M$19.38M$10.68MUnavailableUnavailable$28.52MUnavailable
Current liabilities$17.49M$10.60M$17.91M$10.42MUnavailableUnavailable$27.98MUnavailable
Total equity incl. NCI$277.59M$304.56M$205.57M-$183.14M-$171.23M-$158.24M-$144.24M-$122.53M
Temporary (mezzanine) equityUnavailableUnavailable$0$257.00MUnavailableUnavailable$191.78MUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$5.04M$4.04M$7.76M$3.58MUnavailableUnavailable$8.26MUnavailable

Cash flow

Evommune, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Operating cash flow-$20.32M-$27.50M-$16.70M-$9.64M-$26.21M-$23.90M-$18.51MUnavailable
Capital expenditures$183.00K$83.00K$104.00K$131.00K$0$0$0Unavailable
Investing cash flow$31.29M-$85.36M-$122.90M-$23.91M$18.00M$13.50M-$33.08MUnavailable
Financing cash flow$532.00K$117.11M$156.85M-$274.00K$64.34M-$152.00K$49.70MUnavailable
Net change in cash$11.51M$4.25M$17.25M-$33.82M$56.13M-$10.55M-$1.89MUnavailable
Stock-based compensation$4.60M$3.45M$4.20M$560.00K$556.00K$544.00K$494.00KUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$200.00K$100.00K$326.00K$311.00K$200.00K$200.00K$360.00KUnavailable

Derived

Evommune, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Free cash flow-$20.50M-$27.59M-$16.80M-$9.77M-$26.21M-$23.90M-$18.51MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable-133.3%Unavailable-501.1%UnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable-97.7%Unavailable-796.6%UnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable5.6%Unavailable18.1%UnavailableUnavailable
Current ratio11.68x20.36x8.57x7.87xUnavailableUnavailable2.64xUnavailable
Revenue YoY growthUnavailable-100.0%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable-124.8%Unavailable-485.2%UnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable196.4%Unavailable478.7%UnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable1.3%Unavailable0.0%UnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open EVMN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-12-11View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.